Дедов И.И., Шестакова М.В., Майоров А.Ю. (ред.). Алгоритмы специализированной медицинской помощи больным сахарным диабетом. 9-й выпуск. Сахарный диабет. 2019;22(1S1):1-144. doi: 10.14341/DM221S1..
DOI: 10.14341/DM221S1
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003;26(1 Suppl.):s5-s20. doi: doi: 10.2337/diacare.26.2007.s5..
DOI: 10.2337/diacare.26.2007.s5
Chen C., Zhao X.L., Li Z.H., Zhu Z.G., Qian S.H., Flewitt A.J. Current and Emerging Technology for Continuous Glucose Monitoring. Sensors (Basel). 2017;19;17(1):182. doi: 10.3390/s17010182..
DOI: 10.3390/s17010182
Mian Z., Hermayer K.L., Jenkins A. Continuous Glucose Monitoring: Review of an Innovation in Diabetes Management. Am J Med Sci. 2019;358(5): 332-339. doi: 10.1016/j.amjms.2019.07.003..
DOI: 10.1016/j.amjms.2019.07.003
Ang E., Lee Z.X., Moore S., Nana M. Flash glucose monitoring (FGM): A clinical review on glycaemic outcomes and impact on quality of life. J Diabetes Complications. 2020;34(6):107559. doi: 10.1016/j.jdiaco-mp.2020.107559..
DOI: 10.1016/j.jdiaco-mp.2020.107559
Ang E., Lee Z.X., Moore S., Nana M. Flash glucose monitoring (FGM): A clinical review on glycaemic outcomes and impact on quality of life. J Diabetes Complications. 2020;34(6):107559. doi: 10.1016/j.jdiaco-mp.2020.107559..
DOI: 10.1016/j.jdiacomp.2020.107559
Huggins C., Hodges C.V. Studies on prostatic cancer: I. The effect of castration, of estogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. J Urology. 1941;1:293-297.
Bell K.J., Del Mar C., Wright G., Dickinson J., Glasziou P. Prevalence of incidental prostate cancer: A systematic review of autopsy studies. Int J Cancer. 2015;1;137(7):1749-1757. doi: 10.1002/ijc.29538..
DOI: 10.1002/ijc.29538
Ferlay J., Colombet M., Soerjomataram I., Mathers C., Parkin D.M., Pineros M. et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144(8): 1941-1953. doi: 10.1002/ijc.31937..
DOI: 10.1002/ijc.31937
Каприн А.Д., Старинский В.В., Шахзадова А.О. (ред.). Состояние онкологической помощи населению России в 2019 году. М.: МНИОИ им. П.А. Герцена - филиал ФГБУ «НМИЦ радиологии» Минздрава России; 2020. 239 с. Режим доступа https://glavonco.ru/cancer_register/Pomoshch[%]202019.pdf.https://glavonco.ru/cancer_register/Pomoshch[%]202019.pdf
Каприн А.Д., Старинский В.В., Шахзадова А.О. (ред.). Состояние онкологической помощи населению России в 2019 году. М.: МНИОИ им. П.А. Герцена - филиал ФГБУ «НМИЦ радиологии» Минздрава России; 2020. 239 с. Режим доступа https://glavonco.ru/cancer_register/Pomoshch[%]202019.pdf.https//glavonco.ru/cancer_register/Pomoshch[%]202019.pdf
Stellato R.K., Feldman H.A., Hamdy O., Horton E.S., McKinlay J.B. Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts male aging study. Diabetes Care. 2000;23(4):490-494. doi: 10.2337/diacare.23.4.490..
DOI: 10.2337/diacare.23.4.490
Oh J.Y., Barrett-Connor E., Wedick N.M., Wingard D.L. Rancho Bernardo Study. Endogenous sex hormones and the development of type 2 diabetes in older men and women: the Rancho Bernardo study. Diabetes Care. 2002;25(1):55-60. doi: 10.2337/diacare.25.1.55..
DOI: 10.2337/diacare.25.1.55
Jones T.H., Arver S., Behre H.M., Buvat J., Meuleman E., Moncada I. et al. TIMES2 Investigators. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care. 2011;34(4):828-837. doi: 10.2337/dc10-1233..
DOI: 10.2337/dc10-1233
Hackett G., Cole N., Bhartia M., Kennedy D., Raju J., Wilkinson P. Testosterone replacement therapy improves metabolic parameters in hypogonadal men with type 2 diabetes but not in men with coexisting depression: the BLAST study. J Sex Med. 2014;11(3):840-856. doi: 10.1111/jsm.12404..
DOI: 10.1111/jsm.12404
Keating N.L., O'Malley A.J., Smith M.R. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24(27):4448-4456. doi: 10.1200/JCO.2006.06.2497..
DOI: 10.1200/JCO.2006.06.2497
Smith J.C., Bennett S., Evans L.M., Kynaston H.G., Parmar M., Mason M.D. et al. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab. 2001;86(9):4261-4267. doi: 10.1210/jcem.86.9.7851..
DOI: 10.1210/jcem.86.9.7851
Hamilton E.J., Gianatti E., Strauss B.J., Wentworth J., Lim-Joon D., Bolton D. et al. Increase in visceral and subcutaneous abdominal fat in men with prostate cancer treated with androgen deprivation therapy. Clin Endocrinol (Oxf). 2011;74(3):377-383. doi: 10.1111/j.1365-2265.2010.03942.x..
DOI: 10.1111/j.1365-2265.2010.03942.x
Mitsuzuka K., Kyan A., Sato T., Orikasa K., Miyazato M., Aoki H. et al. Influence of 1 year of androgen deprivation therapy on lipid and glucose metabolism and fat accumulation in Japanese patients with prostate cancer. Prostate Cancer Prostatic Dis. 2016;19(1):57-62. doi: 10.1038/pcan.2015.50..
DOI: 10.1038/pcan.2015.50
Emerging Risk Factors Collaboration, Sarwar N., Gao P., Seshasai S.R., Gobin R., Kaptoge S., Di Angelantonio E et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010:26;375(9733):2215-2222. doi: 10.1016/S0140-6736(10)60484-9..
DOI: 10.1016/S0140-6736(10)60484-9
Vistisen D., Witte D.R., Brunner E.J., Kivimäki M., Tabák A., Jørgensen M.E., Færch K. Risk of cardiovascular disease and death in individuals with prediabetes defined by different criteria: the whitehall II study. Diabetes Care. 2018;41(4):899-906. doi: 10.2337/dc17-2530..
DOI: 10.2337/dc17-2530
Tang X., Li S., Wang Y., Wang M., Yin Q., Mu P. et al. Glycemic variability evaluated by continuous glucose monitoring system is associated with the 10-y cardiovascular risk of diabetic patients with well-controlled HbA1c. Clin Chim Acta. 2016;461:146-150. doi: 10.1016/j.cca.2016.08.004..
DOI: 10.1016/j.cca.2016.08.004
Салухов В.В., Кицышин В.П., Улупова Е.О., Титов Д.Г. Рациональное применение показателей вариабельности глюкозы в практике эндокринолога. Medline.ru. Российский биомедицинский журнал. 2018;19(4):819-831. Режим доступа: http://www.medline.ru/public/art/tom19/art60.html.http://www.medline.ru/public/art/tom19/art60.html
Салухов В.В., Кицышин В.П., Улупова Е.О., Титов Д.Г. Рациональное применение показателей вариабельности глюкозы в практике эндокринолога. Medline.ru. Российский биомедицинский журнал. 2018;19(4):819-831. Режим доступа: http://www.medline.ru/public/art/tom19/art60.html.http://www.medline.ru/public/art/tom19/art60.html
Cheung A.S., Hoermann R., Dupuis P., Joon D.L., Zajac J.D., Grossmann M. Relationships between insulin resistance and frailty with body composition and testosterone in men undergoing androgen deprivation therapy for prostate cancer. Eur J Endocrinol. 2016;175(3):229-237. doi: 10.1530/EJE-16-0200..
DOI: 10.1530/EJE-16-0200
Marin P., Oden B., Bjorntorp P. Assimilation and mobilization of triglycerides in subcutaneous abdominal and femoral adipose tissue in vivo in men: effects of androgens. J Clin Endocrinol Metab. 1995;80(1):239-243. doi: 10.1210/jcem.80.1.7829619..
DOI: 10.1210/jcem.80.1.7829619
Gupta V., Bhasin S., Guo W., Singh R., Miki R., Chauhan P. et al. Effects of dihydrotestosterone on differentiation and proliferation of human mesenchymal stem cells and preadipocytes. Mol Cell Endocrinol. 2008;296 (1-2):32-40. doi: 10.1016/j.mce.2008.08.019..
DOI: 10.1016/j.mce.2008.08.019
Chang D., Joseph DJ., Ebert M.A., Galvao D.A., Taaffe D.R., Denham J.W. et al. Effect of androgen deprivation therapy on muscle attenuation in men with prostate cancer. J Med Imaging Radiat Oncol. 2014;58(2):223-228. doi: 10.1111/1754-9485.12124..
DOI: 10.1111/1754-9485.12124
Hegarty B.D., Furler S.M., Ye J., Cooney G.J., Kraegen E.W. The role of intramuscular lipid in insulin resistance. Acta Physiol Scand. 2003;178(4): 373-383. doi: 10.1046/j.1365-201X.2003.01162.x..
DOI: 10.1046/j.1365-201X.2003.01162.x
Navarro G., Xu W., Jacobson D.A., Wicksteed B., Allard C., Zhanget G. et al. Extranuclear actions of the androgen receptor enhance glucose-stimulated insulin secretion in the male. Cell Metab. 2016;23(5):837-851. doi: 10.1016/j.cmet.2016.03.015..
DOI: 10.1016/j.cmet.2016.03.015
Sezer H., Yazici D., Copur S., Dagel T., Deyneli O., Kanbay M. The relationship between glycemic variability and blood pressure variability in normoglycemic normotensive individuals. Blood Press Monit. 2021;26(2): 102-107. doi: 10.1097/MBP.0000000000000491..
DOI: 10.1097/MBP.0000000000000491
Alatawi Z., Mirghani H. The Association Between Glycemic Variability and Myocardial Infarction: A Review and Meta-Analysis of Prospective Studies and Randomized Trials. Cureus. 2020;12(11):e11556. doi: 10.7759/cureus.11556..
DOI: 10.7759/cureus.11556
Демидова Т.Ю., Кишкович Ю.С. Предиабет: современное состояние проблемы и возможности коррекции. РМЖ. Медицинское обозрение. 2019;10(II):60-67. Режим доступа: https://www.rmj.ru/articles/endokrinologiya/Prediabet_sovremennoe_sostoyanie_problemy_i_vozmoghnosti_korrekcii/#ixzz6t9gCA73S.https://www.rmj.ru/articles/endokrinologiya/Prediabet_sovremennoe_sostoyanie_problemy_i_vozmoghnosti_korrekcii/#ixzz6t9gCA73S
Демидова Т.Ю., Кишкович Ю.С. Предиабет: современное состояние проблемы и возможности коррекции. РМЖ. Медицинское обозрение. 2019;10(II):60-67. Режим доступа: https://www.rmj.ru/articles/endokrinologiya/Prediabet_sovremennoe_sostoyanie_problemy_i_vozmoghnosti_korrekcii/#ixzz6t9gCA73S.https://www.rmj.ru/articles/endokrinologiya/Prediabet_sovremennoe_sostoyanie_problemy_i_vozmoghnosti_korrekcii/#ixzz6t9gCA73S
Margel D., Urbach D.R., Lipscombe L.L., Bell C.M., Kulkarni G., Austin P.C. et al. Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes. J Clin Oncol. 2013;31(25):3069-3075. doi: 10.1200/JCO.2012.46.7043..
DOI: 10.1200/JCO.2012.46.7043
Richards K.A., Liou J.I., Cryns V.L., Downs T.M., Abel E.J., Jarrard D.F. Metformin Use is Associated with Improved Survival for Patients with Advanced Prostate Cancer on Androgen Deprivation Therapy. J Urol. 2018;200(6):1256-1263. doi: 10.1016/j.juro.2018.06.031..
DOI: 10.1016/j.juro.2018.06.031
Lee M.J., Jayalath V., Xu W., Lu L., Freedland S.J., Fleshner N.E. et al. Association between metformin medication, genetic variation and prostate cancer risk. Prostate Cancer Prostatic Dis. 2021;24(1):96-105. doi: 10.1038/s41391-020-0238-y..
DOI: 10.1038/s41391-020-0238-y
Nobes J.P., Langley S.E., Klopper T., Russell-Jones D., Laing R.W. A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy. BJU Int. 2012;109(10):1495-1502. doi: 10.1111/j.1464-410X.2011.10555.x..
DOI: 10.1111/j.1464-410X.2011.10555.x